Welcome to industryreportstore.com

Browse the latest reports in the Therapy Area industry below

2275 Item(s)

Page 1 of 228

  1. EpiCast Report: Allergic Rhinitis - Epidemiology Forecast to 2023 more info

    Allergic rhinitis is a chronic respiratory disease characterized by inflammation of the nasal cavity and affects people of all ages. The main symptoms of allergic rhinitis are sneezing, nasal itching, blocked or runny nose and sore throat. Research suggests that a combination of genetic factors such as family history of allergic rhinitis and environmental factors such as exposure to allergens, including smoke, dust, pollen, insects, molds, or animal dander, may increase the risk for developing allergic rhinitis. According to the World Health Organization, an estimated 400 million people worldwide were affected with allergic rhinitis during 1996–2006.
    By: GlobalData
    , Published: Apr-2014
    , Product code: GDHCER057
    PAGES: 49 TABLES: 14 FIGURES & CHARTS: 4
    $3,995.00
  2. OpportunityAnalyzer: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017 more info

    With five-year survival only approximately 5%, pancreatic cancer is characterized as a disease with some of the highest unmet need in oncology. This report focuses on the current treatment landscape, unmet needs, pipeline and commercial opportunity in the pancreatic cancer market with coverage of both the early stage resectable and advanced settings. Celgene’s Abraxane was launched in the US and Europe in 2013 and 2014, respectively, and was the first drug approved in this disease in nearly a decade. Due to the high unmet need, GlobalData forecasts the rapid uptake of Abraxane, and sales of this drug are expected to drive the overall pancreatic cancer market and are forecast to represent greater than 50% of total market sales in 2017. GlobalData also forecasts the launch of five new pipeline agents into the pancreatic cancer market. Despite the launch of new agents, GlobalData expects significant opportunities to remain for developers of drugs with predictive biomarker-driven strategies. The challenge for new entrants will be to design adequate clinical studies that assess pipeline drugs in carefully selected patient populations and incorporate the current standard-of-care chemotherapies, such as GemAbrax, as backbone regimens. With Big Pharma being actively involved in early-stage innovative projects, GlobalData expects clinical development in pancreatic cancer to accelerate at the end of the forecast period and beyond.
    By: GlobalData
    , Published: Mar-2014
    , Product code: GDHC016POA
    PAGES: 179 TABLES: 38 FIGURES & CHARTS: 16
    $5,995.00
  3. EpiCast Report: Ankylosing Spondylitis - Epidemiology Forecast to 2022 more info

    Ankylosing spondylitis is a systemic, chronic, and progressive inflammatory arthritis in the family of seronegativespondyloarthritis, and is one of the most common rheumatic conditions throughout the world. Ankylosing spondylitis primarily affects the spine and sacroiliac joints, with involvement with other joints in the shoulders, hips, and knees. It can progress into severe inflammation that fuses the spine, leading to permanent painful stiffness of the back. Although treatment helps in relieving pain and stiffness and keeps the spine flexible, the disease is irreversible and people with the disorder have to cope with symptoms throughout their lives. Global prevalence of the disease ranges from 0.01%–1.40%, with higher prevalence in western European Caucasian populations. The epidemiology of ankylosing spondylitis follows a specific geographic distribution mirroring the global variation in prevalence of the HLA-B27 risk allele.
    By: GlobalData
    , Published: Mar-2014
    , Product code: GDHCER056
    PAGES: 49 TABLES: 11 FIGURES & CHARTS: 5
    $3,995.00
  4. OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017 - Event-Driven Update more info

    GlobalData has released its new Opportunity Analyzer report, “OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017 - Event-Driven Update”. The NASH market is currently deserted and awaits its first NASH-specific therapy. With novel mechanism of action awaiting approval such as: Genfit’s PPAR agonist, GFT505 and Intercept Pharmaceuticals/Dainippon Sumitomo Pharma’s FXR agonist, Obeticholic Acid. These compounds will race to be the first approved therapy thus claiming first in class.
    By: GlobalData
    , Published: Mar-2014
    , Product code: GDHC034POA
    PAGES: 117 TABLES: 32 FIGURES & CHARTS: 10
    $5,995.00
  5. Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability more info

    GBI Research, the leading business intelligence provider, has released its latest research, "Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability", which provides in-depth analysis of epilepsy market within the Asia-Pacific (APAC) market covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.
    By: GBI Research
    , Published: Mar-2014
    , Product code: GBIHC324MR
    PAGES: 66 TABLES: 14 FIGURES & CHARTS: 22
    $3,500.00
  6. NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool more info

    GBI Research, the leading business intelligence provider, has released its latest research, "NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool", which provides in-depth insights into the Non-Small Cell Lung Cancer (NSCLC) indication. The report provides an estimation of the market size for 2012 along with market forecasts until 2019 for the Asia-Pacific (APAC) region, covering Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, clinical trial analysis (including failure rates), pipeline analysis, and analysis of deals relevant to NSCLC. The NSCLC market in the APAC region is estimated to have been worth $1.8 billion in 2012 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.3% to reach $2.9 billion by 2019. The key drivers for this growth include an aging population, an increasing number of NSCLC incident cases and the expected launch of promising therapies. The launch of premium-priced novel antibodies and immunotherapies in the first and second lines of therapy, including Boehringer Ingelheim’s Gilotrif, Eli Lilly’s necitumumab, Bristol-Myers Squibb’s Yervoy (ipilimumab) and nivolumab, Pfizer’s dacomitinib and Novartis’s LDK378 are set to drive the market during the forecast period. However, the recent implementation of a price ceiling on essential drugs,dominance of generic drugs in India and expected pricing restrictions in China could curtail the NSCLC market in APAC countries.
    By: GBI Research
    , Published: Mar-2014
    , Product code: GBIHC326MR
    PAGES: 109 TABLES: 15 FIGURES & CHARTS: 29
    $3,500.00
  7. Epilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs with Novel Mechanisms of Action Signal a Shift in Treatment Patterns more info

    GBI Research has released its pharma research, "Epilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs with Novel Mechanisms of Action Signal a Shift in Treatment Patterns", which provides in-depth analysis of epilepsy market within the eight major developed markets of the US, UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of the market size for 2012, along with market forecasts to 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.
    By: GBI Research
    , Published: Mar-2014
    , Product code: GBIHC325MR
    PAGES: 74 TABLES: 18 FIGURES & CHARTS: 25
    $3,500.00
  8. OpportunityAnalyzer: Autism Spectrum Disorder - Opportunity Analysis and Forecasts to 2018 more info

    Autism Spectrum Disorders (ASD) is a chronically underserved market currently dominated by the two approved drugs, both of which are antipsychotics. There is off-label use of a multitude of other drugs which target different core and non-core symptoms of ASD. Since this disorder can first become apparent in very young children there is a need for medications which are safe and effective in the pediatric population. The ASD market is expected to grow remain relatively flat between 2012 and 2018, which is predominantly due to various drug patent expiration, and the introduction of novel therapies in the US and EU countries is not anticipated to offset this expected decline in the market. The new treatments will target some key unmet needs but opportunities will remain for drugs which can effectively target any of the many core and non-core symptoms of ASD, as well as offering an improved safety profile over currently used drugs.
    By: GlobalData
    , Published: Mar-2014
    , Product code: GDHC009POA
    PAGES: 214 TABLES: 35 FIGURES & CHARTS: 11
    $5,995.00
  9. PharmaSphere: Emerging Biotech Investment Report - Strategic Trends in Private Equity and Venture Capital Funding more info

    GlobalData’s "PharmaSphere: Emerging Biotech Investment Report - Strategic Trends in Private Equity and Venture Capital Funding" report provides in-depth analysis of the current trends and factors shaping the private equity and venture capital segments of the financial industry, bearing in mind that these are expected to have significant impact on the future of emerging biotechnology companies in the US and globally. Furthermore, the report identifies regions of the world that are attracting more investments in healthcare and discusses the various factors responsible for this trend. In addition, the report provides detailed profiles of 12 leading private equity firms, 15 top venture capital firms, and 15 US-based emerging biotechnology companies that completed initial public offerings in 2013.
    By: GlobalData
    , Published: Mar-2014
    , Product code: GDHC005PSR
    PAGES: 183 TABLES: 38 FIGURES & CHARTS: 65
    $2,995.00
  10. Chronic Bronchitis - Pipeline Review, H1 2014 more info

    Global Markets Direct’s, ‘Chronic Bronchitis - Pipeline Review, H1 2014’, provides an overview of the Chronic Bronchitis’s therapeutic pipeline.
    By: Global Markets Direct
    , Published: Feb-2014
    , Product code: GMDHC4635IDB
    PAGES: 64 TABLES: 24 FIGURES & CHARTS: 14
    $2,000.00

2275 Item(s)

Page 1 of 228